fda tirzepatide shortage resolved 2025 says years-long is resolved, will give limited leeway to compounders FDA confirms tirzepatide shortage is

With retatrutide, in 2026, there is no such path

The choice between them is not arbitrary, but the reasoning differs depending on the delivery method

Liraglutide stands out for having the strongest direct evidence of platelet inhibition, the controlled study showing 54% reduction in thromboxane-induced aggregation

Consumers who choose less expensive copies of Zepbound or Mounjaro because their insurance company does not cover GLP-1 drugs might switch to semaglutide in the short-term, said Geoff Cook, CEO of Noom, a subscription-based weight-loss company that offers compounded semaglutide

It's Dangerous for People Who Aren't Overweight to Take Ozempic Using GLP-1 medications without meeting prescribing criteria can expose someone to unnecessary risks without meaningful benefit

3094 In Re: GLP-1 Receptor Agonists Products Liability Litigation